BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
biocon limited. stock

BIOCON LIMITED. Share Price

352.8 -3.90 (-1.09%)
Dec 13 2024 03:30 PM Pharmaceuticals NSE: BIOCON

BIOCON LIMITED. Share Price Update

As of the latest trading session, BIOCON LIMITED. share price is currently at 352.8, which is down by -3.90 from its previous closing. Today, the stock has fluctuated between 346.75 and 356.80. Over the past year, BIOCON LIMITED. has achieved a return of 41.51 %. In the last month alone, the return has been 6.40 %. Read More...

BIOCON LIMITED. Performance

Day Range

Low346.75 High356.80
352.80

52 Week Range

Low 238.25 High 395.80
352.80

BIOCON LIMITED. Share Price

11373

532523

BIOCON

img img img img
No Data Available

Open Price

356.00

Prev. Close

356.70

Volume (Shares)

2638692.00

Total traded value

9309.30

Upper Circuit

392.35

Lower Circuit

321.05

Note: The current prices & values are delayed, Login to your account for live updates.

BIOCON LIMITED. Fundamentals


(Standalone)

Market Cap (Cr) 42357.17
PE Ratio (TTM) 1007.71
Book Value / Share 90.69
Beta 1.08
ROE 0.97%
EPS (TTM) 0.35
Dividend Yield 0.14%
Net Profit Qtr (Cr) 3.20

BIOCON LIMITED. Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 525.40
Operating Expense 578.00
Net Profit 3.20
Net Profit Margin (%) 0.60
Earnings Per Share (EPS) 0.03
EBITDA 111.10
Effective Tax Rate (%) 84.68
Particulars JUN 2024 (Values in Cr)
Revenue 510.60
Operating Expense 551.40
Net Profit 0.90
Net Profit Margin (%) 0.17
Earnings Per Share (EPS) 0.01
EBITDA 86.80
Effective Tax Rate (%) 18.18
Particulars MAR 2024 (Values in Cr)
Revenue 532.60
Operating Expense 549.70
Net Profit 14.00
Net Profit Margin (%) 2.62
Earnings Per Share (EPS) 0.12
EBITDA 91.10
Effective Tax Rate (%) 35.77
Particulars DEC 2023 (Values in Cr)
Revenue 562.80
Operating Expense 578.40
Net Profit 24.00
Net Profit Margin (%) 4.26
Earnings Per Share (EPS) 0.20
EBITDA 119.80
Effective Tax Rate (%) 27.05
Particulars SEP 2023 (Values in Cr)
Revenue 518.70
Operating Expense 537.10
Net Profit 34.70
Net Profit Margin (%) 6.68
Earnings Per Share (EPS) 0.29
EBITDA 131.60
Effective Tax Rate (%) 24.56
Particulars MAR 2024 (Values in Cr)
Revenue 2127.30
Operating Expense 2184.50
Net Profit 119.30
Net Profit Margin (%) 5.60
Earnings Per Share (EPS) 1.00
EBITDA 470.20
Effective Tax Rate (%) 20.62
Particulars MAR 2023 (Values in Cr)
Revenue 1992.90
Operating Expense 2155.90
Net Profit 2848.40
Net Profit Margin (%) 142.92
Earnings Per Share (EPS) 23.87
EBITDA 3157.70
Effective Tax Rate (%) 4.13
Particulars MAR 2022 (Values in Cr)
Revenue 1738.20
Operating Expense 1785.70
Net Profit 86.10
Net Profit Margin (%) 4.95
Earnings Per Share (EPS) 0.72
EBITDA 248.30
Effective Tax Rate (%) 38.36
Particulars MAR 2021 (Values in Cr)
Revenue 2028.40
Operating Expense 1819.80
Net Profit 280.50
Net Profit Margin (%) 13.82
Earnings Per Share (EPS) 2.36
EBITDA 462.70
Effective Tax Rate (%) 21.82
Particulars MAR 2020 (Values in Cr)
Revenue 1988.40
Operating Expense 1801.60
Net Profit 440.90
Net Profit Margin (%) 22.17
Earnings Per Share (EPS) 3.72
EBITDA 647.40
Effective Tax Rate (%) 20.41
Particulars MAR 2024 (Values in Cr)
Book Value / Share 164.77
ROE % 6.89
ROCE % 6.35
Total Debt to Total Equity 0.91
EBITDA Margin 27.57
Particulars MAR 2023 (Values in Cr)
Book Value / Share 148.81
ROE % 6.64
ROCE % 5.68
Total Debt to Total Equity 0.88
EBITDA Margin 24.57
Particulars MAR 2022 (Values in Cr)
Book Value / Share 70.23
ROE % 10.84
ROCE % 7.55
Total Debt to Total Equity 0.60
EBITDA Margin 24.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 63.55
ROE % 11.81
ROCE % 8.68
Total Debt to Total Equity 0.50
EBITDA Margin 25.77
Particulars MAR 2020 (Values in Cr)
Book Value / Share 55.87
ROE % 13.61
ROCE % 12.17
Total Debt to Total Equity 0.40
EBITDA Margin 28.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 90.88
ROE % 0.97
ROCE % 2.61
Total Debt to Total Equity 0.15
EBITDA Margin 21.31
Particulars MAR 2023 (Values in Cr)
Book Value / Share 90.91
ROE % -0.14
ROCE % 1.50
Total Debt to Total Equity 0.07
EBITDA Margin 13.60
Particulars MAR 2022 (Values in Cr)
Book Value / Share 67.40
ROE % 1.08
ROCE % 1.72
Total Debt to Total Equity 0.01
EBITDA Margin 14.28
Particulars MAR 2021 (Values in Cr)
Book Value / Share 65.88
ROE % 3.63
ROCE % 4.60
Total Debt to Total Equity 0.00
EBITDA Margin 22.81
Particulars MAR 2020 (Values in Cr)
Book Value / Share 62.80
ROE % 4.16
ROCE % 5.17
Total Debt to Total Equity 0.01
EBITDA Margin 24.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2258.70
Total Assets 56070.70
Total Liabilities 56070.70
Total Equity 25274.80
Share Outstanding 1200600000
Price to Book Ratio 2.91
Return on Assets (%) 1.82
Return on Capital (%) 2.49
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2400.10
Total Assets 52042.80
Total Liabilities 52042.80
Total Equity 22488.80
Share Outstanding 1200600000
Price to Book Ratio 2.27
Return on Assets (%) 0.88
Return on Capital (%) 1.15
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1747.50
Total Assets 20394.00
Total Liabilities 20394.00
Total Equity 9470.00
Share Outstanding 1200600000
Price to Book Ratio 4.96
Return on Assets (%) 3.17
Return on Capital (%) 4.51
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2015.40
Total Assets 18522.30
Total Liabilities 18522.30
Total Equity 8507.60
Share Outstanding 1200000000
Price to Book Ratio 6.21
Return on Assets (%) 3.99
Return on Capital (%) 5.76
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 998.60
Total Assets 14443.80
Total Liabilities 14443.80
Total Equity 7383.10
Share Outstanding 1200000000
Price to Book Ratio 4.31
Return on Assets (%) 5.18
Return on Capital (%) 8.07
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 585.70
Total Assets 13768.20
Total Liabilities 13768.20
Total Equity 10912.30
Share Outstanding 1200600000
Price to Book Ratio 2.91
Return on Assets (%) 0.86
Return on Capital (%) 0.92
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 720.30
Total Assets 13029.90
Total Liabilities 13029.90
Total Equity 10916.00
Share Outstanding 1200600000
Price to Book Ratio 2.27
Return on Assets (%) 21.86
Return on Capital (%) 23.32
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 689.30
Total Assets 8869.00
Total Liabilities 8869.00
Total Equity 8092.90
Share Outstanding 1200600000
Price to Book Ratio 4.96
Return on Assets (%) 0.97
Return on Capital (%) 1.05
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 601.20
Total Assets 8573.70
Total Liabilities 8573.70
Total Equity 7907.10
Share Outstanding 1200000000
Price to Book Ratio 6.21
Return on Assets (%) 3.27
Return on Capital (%) 3.55
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 375.30
Total Assets 8310.80
Total Liabilities 8310.80
Total Equity 7537.30
Share Outstanding 1200000000
Price to Book Ratio 4.31
Return on Assets (%) 5.30
Return on Capital (%) 5.85
Particulars MAR 2024 (Values in Cr)
Net Income 1297.80
Cash from Operations 3246.20
Cash from Investing -1004.50
Cash from Financing -2332.70
Net change in Cash -383.30
Free Cash Flow 4926.70
Particulars MAR 2023 (Values in Cr)
Net Income 643.00
Cash from Operations 2081.10
Cash from Investing -14281.80
Cash from Financing 13048.70
Net change in Cash 619.40
Free Cash Flow 3677.10
Particulars MAR 2022 (Values in Cr)
Net Income 771.60
Cash from Operations 1438.60
Cash from Investing -1699.10
Cash from Financing 242.10
Net change in Cash -280.40
Free Cash Flow 3136.39
Particulars MAR 2021 (Values in Cr)
Net Income 846.20
Cash from Operations 1353.50
Cash from Investing -3624.70
Cash from Financing 2564.00
Net change in Cash 99.00
Free Cash Flow 2870.40
Particulars MAR 2020 (Values in Cr)
Net Income 870.90
Cash from Operations 1627.20
Cash from Investing -1558.90
Cash from Financing 387.60
Net change in Cash 111.80
Free Cash Flow 3231.40
Particulars MAR 2024 (Values in Cr)
Net Income 119.30
Cash from Operations -95.70
Cash from Investing -296.40
Cash from Financing 343.60
Net change in Cash -76.00
Free Cash Flow 206.00
Particulars MAR 2023 (Values in Cr)
Net Income 2848.40
Cash from Operations 260.40
Cash from Investing -1177.80
Cash from Financing 1039.40
Net change in Cash 80.90
Free Cash Flow 522.30
Particulars MAR 2022 (Values in Cr)
Net Income 86.10
Cash from Operations 76.00
Cash from Investing -305.60
Cash from Financing 112.00
Net change in Cash -146.00
Free Cash Flow 315.20
Particulars MAR 2021 (Values in Cr)
Net Income 280.50
Cash from Operations 632.60
Cash from Investing -711.20
Cash from Financing 27.80
Net change in Cash -112.10
Free Cash Flow 780.30
Particulars MAR 2020 (Values in Cr)
Net Income 440.90
Cash from Operations 477.80
Cash from Investing -212.90
Cash from Financing -128.90
Net change in Cash 45.30
Free Cash Flow 673.10
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 36.86 3.50 491.45 37.54 / 77.70
BLISS GVS PHARMA LTD 175.85 22.01 1.83 1852.87 92.25 / 179.65
CIPLA LTD 1447.35 25.32 4.12 116889.80 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 403.70 140.17 4.09 1188.13 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 55.77 10.90 491.45 37.54 / 77.70
AMRUTAJAN HEALTH LTD 749.90 45.61 7.28 2168.01 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6603.60 128.25 24.30 16509.00 4050.15 / 8139.85
BLISS GVS PHARMA LTD 175.85 22.93 1.80 1852.87 92.25 / 179.65

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 362.30
  • 26 Days 352.70
  • 10 Days 365.60
  • 50 Days 351.80
  • 12 Days 365.20
  • 100 Days 348.10
  • 20 Days 357.80
  • 200 Days 281.40
360.52
PIVOT
First Resistance 365.53
Second Resistance 374.37
Third Resistance 379.38
First Support 351.68
Second Support 346.67
Third Support 337.83
RSI 48.73
MACD 12.49
Commodity Channel Index (CCI) -15.11
ADX 36.90
Williams % R -63.15

Over 1 Month

down

6.40

Over 3 Months

down

-6.90

Over 6 Months

down

4.33

Over 1 Year

down

41.51

Over 3 Years

down

-2.31

Over 5 Years

down

3.83

BIOCON LIMITED. Future

Future: Price

26 Dec
354.20
30 Jan
357.20
27 Feb
359.00
25 May
0 100 200 300 400 500 600

Discount/Premium

26 Dec
1.40
30 Jan
4.40
27 Feb
6.20
25 May
0 1 2 3 4 5 6 7

Active Calls

360.0
1370
400.0
1307
380.0
1181
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

350.0
1070
345.0
562
340.0
512
25 Jul
0 500 1000 1500 2000 2500

BIOCON LIMITED. Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
18.99
Promoter Holdings
60.63
FII
5.92
DII
14.43
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Kiran Mazumdar Shaw Shareholding of Promoter and Promoter Group 4.8458197E8 40.36
Glentec International Shareholding of Promoter and Promoter Group 2.37211164E8 19.76
Lici Ulip-growth Fund Public Shareholding 6.1097235E7 5.09
Sbi Arbitrage Opportunities Fund Public Shareholding 2.9154517E7 2.43
Kotak Esg Opportunities Fund Public Shareholding 1.7474815E7 1.46
Arun Suresh Chandavarkar Public Shareholding 1.32E7 1.1
Ravi Rasendra Mazumdar Shareholding of Promoter and Promoter Group 5301321.0 0.44
Dev Mazumdar Shareholding of Promoter and Promoter Group 929721.0 0.08

BIOCON LIMITED.

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-07-07 1.5 Final 2023-07-07 Equity shares 2022-06-30 0.5 Final 2022-07-01 Equity shares 2019-07-18 0.5 Final 2019-07-19 Equity shares 2018-07-19 1.0 Final 2018-07-20 Equity shares 2017-07-20 1.0 Final 2017-07-22 Equity shares 2016-03-17 5.0 Interim 2016-03-19 Equity shares 2015-04-09 5.0 Interim 2015-04-10 Equity shares 2014-07-10 5.0 Final 2014-07-12 Equity shares 2013-07-11 5.0 Final 2013-07-13 Equity shares 2013-07-11 2.5 Special 2013-07-13 Equity shares 2012-07-05 5.0 Final 2012-07-07 Equity shares 2011-07-07 3.0 Final 2011-07-09 Equity shares 2011-05-05 1.5 Interim 2011-05-06 Equity shares 2010-07-08 3.5 Final 2010-07-10 Equity shares 2009-07-13 3.0 Final 2009-07-10 Equity shares 2008-07-03 3.0 Final 2008-07-05 Equity shares 2008-07-03 2.0 Special 2008-07-05 Equity shares 2007-06-28 3.0 Final 2007-07-02 Equity shares 2005-06-29 0.0 Final 2005-07-10 Equity shares
Ex-Date Ex-Bonus Ratio
2019-06-13 2019-06-12 1:1 2017-06-17 2017-06-15 2:1 2008-09-12 2008-09-11 1:1
Ex-Date Old FV NEW FV Record Date

Biocon Share Result Highlights

Metric

Value

Share Price

₹325.45 (as of 07 Nov 2024)

Daily Change

+2.60 (0.80%) (as of 07 Nov 2024)

Day Range

Low: ₹322.15, High: ₹328.35 (07 Nov 2024)

52-Week Range

Low: ₹222.55, High: ₹395.80 (2024)

Market Capitalization

₹39,073.53 Cr (as of 07 Nov 2024)

PE Ratio (TTM)

922.14 (as of 07 Nov 2024)

Earnings Per Share (EPS)

₹0.35 (TTM as of 07 Nov 2024)

Dividend Yield

0.15% (as of 07 Nov 2024)

Total Traded Volume

11,44,939 shares (as of 07 Nov 2024)

Upper Circuit Limit

₹355.10 (as of 07 Nov 2024)

Lower Circuit Limit

₹290.60 (as of 07 Nov 2024)

Key Highlights

  • In 2024, Biocon share price reached a 52-week low of ₹222.55 and a high of ₹395.80.

  • Biocon’s market cap is valued at ₹39,073.53 Cr as of 07 Nov 2024.

  • A PE ratio of 922.14 reflects Biocon’s high valuation relative to earnings, as of TTM ending 07 Nov 2024.

Biocon Share Annual Reports

Metric

Value

Revenue

₹525.40 Cr (for quarter ending Sep 2024)

Operating Expense

₹578.00 Cr (for quarter ending Sep 2024)

Net Profit

₹3.20 Cr (for quarter ending Sep 2024)

Net Profit Margin

0.60% (for quarter ending Sep 2024)

Earnings Per Share (EPS)

₹0.03 (for quarter ending Sep 2024)

EBITDA

₹111.10 Cr (for quarter ending Sep 2024)

Effective Tax Rate

84.68% (for quarter ending Sep 2024)

Dividend Yield

0.15% (as of 07 Nov 2024)

52-Week Range

Low: ₹222.55, High: ₹395.80 (for 2024)

Key Highlights

  • Revenue for Biocon reached ₹525.40 Cr for the quarter ending Sep 2024.

  • Despite operating expenses of ₹578.00 Cr, Biocon maintained a net profit of ₹3.20 Cr.

  • EPS was relatively low at ₹0.03, reflecting earnings for the quarter ending Sep 2024.

  • Dividend yield stands at 0.15% as of 07 Nov 2024, offering shareholders a modest return.

Biocon Share Dividend

Dividend Details

Value

Latest Dividend Amount

₹1.5 per share (07 Jul 2023)

Dividend Type

Final Dividend (07 Jul 2023)

Previous Dividend

₹0.5 per share (30 Jun 2022)

Dividend Frequency

Annual

Dividend Yield

0.15% (as of 07 Nov 2024)

Historical Dividend Amounts

₹1 per share (20 Jul 2018), ₹5 per share (17 Mar 2016)

Key Highlights

  • The most recent Biocon share dividend was ₹1.5 per share, declared on 07 Jul 2023.

  • Biocon has maintained an annual dividend frequency, with varying amounts over the years.

  • In 2024, dividend yield stands at 0.15%, reflecting a steady return for shareholders.

  • Historical dividends include ₹1 per share in 2018 and a high of ₹5 per share in 2016.

About BIOCON LIMITED.

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by BIOCON LIMITED.

Learn More About Stocks

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Biocon Ltd?

Answer Field

The share price of Biocon Ltd for NSE is ₹ 352.8 and for BSE is ₹ 353.

What is the Market Cap of Biocon Ltd?

Answer Field

The market cap of Biocon Ltd for NSE is ₹ 4,23,57.17 Cr. and for BSE is ₹ 4,23,81.18 Cr. as of now.

What is the 52 Week High and Low of Biocon Ltd?

Answer Field

The 52 Week High and Low of Biocon Ltd for NSE is ₹ 395.80 and ₹ 239.30 and for BSE is ₹ 395.65 and ₹ 239.45.

How to Buy Biocon Ltd share?

Answer Field

You can trade in Biocon Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Biocon Ltd?

Answer Field

The 1 year returns on the stock has been 41.51%.

What is the Current Share Price of Biocon Ltd?

Answer Field

Biocon Ltd share price is for NSE ₹ 352.8 & for BSE ₹ 353 as on Dec 13 2024 03:30 PM.

What is the Market Cap of Biocon Ltd Share?

Answer Field

The market cap of Biocon Ltd for NSE ₹ 4,23,57.17 & for BSE ₹ 4,23,81.18 as on Dec 13 2024 03:30 PM.

What is the P/E Ratio of Biocon Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM the price-to-earnings (PE) ratio for Biocon Ltd share is 1007.71.

What is the PB ratio of Biocon Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM, the price-to-book (PB) ratio for Biocon Ltd share is 90.69.

How to Buy Biocon Ltd Share?

Answer Field

You can trade in Biocon Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Biocon Ltd Share on Bajaj Broking App?

Answer Field

To buy Biocon Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Biocon Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Popular FAQs

1. Who is the CEO of Biocon Ltd?

Siddharth Mittal has served as CEO of Biocon Ltd since 1 December 2019. He leads Biocon’s strategic direction, focusing on the company’s growth in biopharmaceuticals and driving its innovations in the global market.

 

2. When was Biocon Ltd established?

Biocon Ltd was established in 1978. It began as a joint venture with Biocon Biochemicals Ltd, Ireland, and has since evolved into a leading biotechnology company, making significant contributions in biopharmaceuticals.

 

3. What factors influence the Biocon Share Price?

The Biocon Share Price is influenced by various factors, including quarterly earnings, regulatory changes, market trends, and developments within the biotechnology sector. Economic conditions and investor sentiment also play a role.

 

4. Is Biocon Ltd debt-free?

No, Biocon Ltd is currently not debt-free. The company strategically uses debt to finance its operations, support expansion plans, and invest in research and development within the biopharmaceutical industry.

 

5. What is the CAGR of Biocon Share?

The Compound Annual Growth Rate (CAGR) of Biocon Share over different time frames is 16% over 10 years, 4% over 5 years, -3% over 3 years, and 42% over 1 year.

 

6. How has the Biocon Share Price performed over the past year?

Over the past year, the Biocon Share Price has risen by 42%, reflecting strong market performance, positive financial results, and heightened investor confidence in Biocon’s strategic direction and growth.

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader